Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.74 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.74 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL175940 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL8568063 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL9449950 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL20362356 | 1.00 | — | — | |
| Leucine SCHEMBL3888 | 1.00 | — | — | |
| D-Leucine SCHEMBL42012 | 1.00 | — | — | |
| Leucine SCHEMBL25241602 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL331557 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL2478164 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL9100148 | 1.00 | SLC7A5 (1.00) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1763083-A | Cyclopentapeptide extraction method and its uses in preparing anti-tumour medicine | UNIV JINAN (CN) | 2006-04-26 | — | — | CN | claimed |
| US-11904053-B2 | Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof | MEDIMMUNE LIMITED (GB) | 2024-02-20 | — | — | US | disclosed |
| EP-4262845-A1 | LIPOCALIN MUTEIN DRY POWDER FORMULATION FOR TREATMENT OF ASTHMA | Astrazeneca AB (SE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230201120-A1 | Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof | PEARL THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20220401365-A1 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | PEARL THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4051708-A1 | DRY POWDER FORMULATIONS OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USE THEREOF | MedImmune Limited (GB) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022129629-A1 | LIPOCALIN MUTEIN DRY POWDER FORMULATION FOR TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022023456-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANO EMBEDDED MICROPARTICLES AND METHODS OF USE | ASTRAZENECA AB (SE) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021083908-A1 | DRY POWDER FORMULATIONS OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USE THEREOF | MEDIMMUNE LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083910-A1 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | ASTRAZENECA AB (SE) | 2021-05-06 | — | — | WO | disclosed |
| US-20210121406-A1 | DRY POWDER FORMULATIONS OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USE THEREOF | MEDIMMUNE, LLC | 2021-04-29 | — | — | US | disclosed |
| CN-1763083-A | Cyclopentapeptide extraction method and its uses in preparing anti-tumour medicine | UNIV JINAN (CN) | 2006-04-26 | — | — | CN | disclosed |
| CN-1763083-A | Cyclopentapeptide extraction method and its uses in preparing anti-tumour medicine | UNIV JINAN (CN) | 2006-04-26 | — | — | CN | disclosed |
| EP-0871430-A1 | IMPROVEMENTS IN AND RELATING TO POWDERS FOR USE IN DRY POWDER INHALERS | CO-ORDINATED DRUG DEVELOPMENT LIMITED (GB) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997003649-A1 | IMPROVEMENTS IN AND RELATING TO POWDERS FOR USE IN DRY POWDER INHALERS | CO-ORDINATED DRUG DEVELOPMENT LTD. (GB) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401365-A1 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | BCAT2, GLUL, SLC1A5 | SLC7A5 13/4885SLC1A2 17/4885SLC1A3 34/4885 |
| US-20210121406-A1 | DRY POWDER FORMULATIONS OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USE THEREOF | TSLP, SERPINA6, CCL11 | SLC7A5 4288/4885SLC1A2 4678/4885SLC1A3 4556/4885 |
| US-11904053-B2 | Dry powder formulations of thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of use thereof | TSLP, SERPINA6, CCL11 | SLC7A5 4288/4885SLC1A2 4678/4885SLC1A3 4556/4885 |
| US-20230201120-A1 | Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof | TSLP, SERPINA6, CCL11 | SLC7A5 4288/4885SLC1A2 4678/4885SLC1A3 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.